

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number 48-03280-01

Docket or Reference number 030-03439

Amendment No. 56

Mount Sinai Medical Center  
950 North Twelfth Street  
P.O. Box 342  
Milwaukee, WI 53201

In accordance with letter dated June 4, 1985, License Number 48-03280-01 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Alberto Lopes Da Conceicao, M.D.

Group VI

Richard H. Christensen, M.D.

Groups I, II, III, IV, V and VI  
Carbon-14, hydrogen-3, iodine-125,  
chromium-51, xenon-133, sulfur-35,  
technetium-99m, cerium-141  
microspheres, strontium-85,  
niobium-95, and ruthenium-103  
microspheres for in vitro and  
animal studies

Donald H. Schmidt, M.D.

Groups II and III  
Carbon-14, hydrogen-3, iodine-125,  
iodine-131, chromium-51,  
xenon-133, sulfur-35,  
technetium-99m, cerium-141  
microspheres, strontium-85,  
niobium-95, and ruthenium-103  
microspheres for in vitro animal  
studies

Uri Vaisman, M.D.

Groups I, II and III  
Xenon-133  
Iodine-131 for treatment of  
hyperthyroidism, cardiac  
dysfunction, and thyroid carcinoma  
Phosphorus-32 as soluble phosphate  
for treatment of polycythemia  
vera, leukemia, and bone  
metastases  
Types, quantities, and forms of  
radioactive materials specified  
in Section 31.11 of 10 CFR Part 31  
for in vitro studies

8507160022 850626  
REQ LIC30  
48-03280-01 PDR

COPY 2

MA30 B JUN 27 1985

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number 48-03280-01

Docket or Reference number  
030-03439

Amendment No. 56

Angel K. Markov, M.D.

Cerium-141 microspheres  
Strontium-85 microspheres

Steven C. Port, M.D.

Groups II and III  
Cerium-141, strontium-85, niobium-95,  
and ruthenium-103 microspheres  
Chromium-51, technetium-99m, and  
xenon-133 for animal studies

V. Shrinivas Murthy, M.D., Ph.D.

Cerium-141, niobium-95 and  
ruthenium-103 microspheres  
Strontium-85, chromium-51, and  
xenon-133 for animal studies

Robert L. Truitt, Ph.D.

In vitro studies  
Animal studies

Abid A. Shah, M.D.

Groups II and III for cardiac  
function and imaging studies  
Xenon-133

Reuben Eisenstein, M.D.

Hydrogen-3, carbon-14, sulfur-35  
iodine-125 and iodine-131 for  
in vitro studies

For the U.S. Nuclear Regulatory Commission

Date June 26, 1985Original Signed  
By Patricia J. Whiston  
Materials Licensing Section, Region III

COPY